surpass-cvot tirzepatide SURPASS-CVOT Investigators - SURPASS-CVOTnejm Tirzepatide was non-inferior to dulaglutide SURPASS-CVOT Tirzepatide: A Deep Dive into Cardiovascular Outcomes

SURPASS-CVOTresults The SURPASS-CVOT trial represents a significant milestone in understanding the cardiovascular impact of tirzepatide, a novel dual incretin agonist. This cardiovascular (CV) outcomes trial was specifically designed to evaluate whether tirzepatide reduces cardiovascular events in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease. The findings from SURPASS-CVOT are crucial for clinicians managing patients with both diabetes and high cardiovascular risk.

SURPASS-CVOT is a randomised clinical trial that compared the effects of once-weekly tirzepatide with dulaglutide, a well-established GLP-1 receptor agonist, on major cardiovascular events. The primary objective was to demonstrate the noninferiority of tirzepatide to dulaglutide in terms of cardiovascular safety. Beyond safety, the trial also aimed to assess the efficacy of tirzepatide in improving various cardiometabolic parametersComparative Study of Tirzepatide Versus Dulaglutide ....

Trial Design and Key Findings

The SURPASS-CVOT trial, involving SURPASS-CVOT Investigators, enrolled participants with type 2 diabetes and a history of atherosclerotic cardiovascular disease. This patient profile is critical, as it targets individuals at high risk for adverse cardiovascular events. The study design, detailed in publications by SJ Nicholls and others, meticulously tracked MACE (Major Adverse Cardiovascular Events), including cardiovascular death, non-fatal myocardial infarction (heart attack), and non-fatal stroke.

Key findings from the SURPASS-CVOT trial indicate that tirzepatide demonstrated a favorable cardiovascular profile. While the trial was designed to establish CV protection with tirzepatide by showing noninferiority to dulaglutide, initial results suggest more profound benefits.作者：SJ Nicholls·2025·被引用次数：16—We conducted the Study ofTirzepatideCompared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS- ... Notably, tirzepatide has been shown to be cardioprotective, with an 8% lower rate of MACE-3 events compared to dulaglutide.In this journal club review, we break down theSURPASS-CVOT trial—the landmark cardiovascular outcomes study comparing tirzepatide versus ... Furthermore, tirzepatide demonstrated broader metabolic and clinical benefits, including significantly greater reductions in HbA1c and body weight... A Study ofTirzepatide(LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT).. For example, the trial reported a 9 mmol/mol difference in HbA1c reduction and a 62025年12月12日—SURPASS-CVOT was designed to establish CV protection with tirzepatideby demonstrating noninferiority of tirzepatide to dulaglutide..8% reduction in body weight for tirzepatide compared to dulaglutide.The Cardiovascular Outcomes in Participants on Tirzepatide ...

The results of SURPASS-CVOT were published in prestigious journals such as the New England Journal of Medicine (NEJM) in December 2025. The study concluded that tirzepatide was noninferior to dulaglutide in preventing cardiovascular death, heart attack, and stroke over a four-year period. While SURPASS-CVOT didn't have a placebo group, these findings are significant, providing a direct comparison between two leading agents in diabetes management with high cardiovascular risk作者：R Aggarwal·2025·被引用次数：1—SURPASS-CVOT is a cardiovascular (CV) outcomes trialevaluating whether tirzepatide reduces CV events in patients with type 2 diabetes (T2D) and established .... One analysis even suggested that tirzepatide appeared superior to dulaglutide in preventing MACE events.

Tirzepatide vs. Dulaglutide: A Comparative Analysis

The comparison between tirzepatide and dulaglutide in SURPASS-CVOT is particularly relevant. Dulaglutide, a GLP-1 receptor agonist, has already established its cardiovascular benefits. SURPASS-CVOT investigated whether tirzepatide, a GIP and GLP-1 receptor agonist, offers comparable or superior cardiovascular outcomes. The trial confirmed that tirzepatide was similar to dulaglutide for prevention of cardiovascular death, heart attack and stroke.The Cardiovascular Outcomes in Participants on Tirzepatide ... However, the added metabolic advantages of tirzepatide, such as greater glycemic control and weight loss, further enhance its clinical utility.

The SURPASS-CVOT study explored various aspects of cardiovascular health. In a pre-specified analysis, the SURPASS-CVOT randomised clinical trial evaluated the comparative effects.SURPASS-CVOT: Tirzepatide Bests Dulaglutide for ... SURPASS-CVOT investigated the cardiovascular outcomes of tirzepatide, a dual incretin agonist. The trial's design and baseline characteristics have been extensively documented, providing a solid foundation for the reported outcomes...SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025 Dec 18;393(24):2409-2420. doi ....

Impact and Future Implications

The findings from SURPASS-CVOT have profound implications for the management of type 2 diabetes in patients with established cardiovascular disease. The dual effectiveness of tirzepatide in both glycemic control and cardiovascular risk reduction positions it as a valuable therapeutic option. The CVOT's demonstration of tirzepatide being cardioprotective offers a new paradigm in diabetes care, aligning with the broader goal of reducing morbidity and mortality associated with diabetes.

While direct placebo comparisons were not part of the primary SURPASS-CVOT design, the comparison against dulaglutide provides robust evidence of tirzepatide's safety and efficacy. The generalizability of SURPASS-CVOT to diverse patient populations, including those in the United States, is an ongoing area of discussion and research.2025年9月18日—▫ Overall,SURPASS-CVOT demonstrated that tirzepatide is cardioprotectivein participants with established atherosclerotic cardiovascular ...

In conclusion, the SURPASS-CVOT trial has provided definitive evidence regarding the cardiovascular outcomes of tirzepatide. It confirms that tirzepatide was non-inferior to dulaglutide in terms of major cardiovascular events, while also offering significant metabolic benefits. This landmark study solidifies the role of tirzepatide in comprehensive diabetes and cardiovascular risk managementLarge Trial Confirms CVD Efficacy of Tirzepatide | tctmd.com.